159634-89-6

Basic information

• Product Name: N-2-(3-BENZYLOXY PRIOPIONIC ACID)-2-(N-T-BUTOXYCAR
• Synonyms: N-2-(3-BENZYLOXY PRIOPIONIC ACID)-2-(N-T-BUTOXYCAR;O-benzyl-N-(2-((tert-butoxycarbonyl)amino)-2-methylpropanoyl)-D-serine;(R)-3-(Benzyloxy)-2-(2-((tert-butoxycarbonyl)amino)-2-methylpropanamido)propanoic acid;EOS-61350
• CAS NO: 159634-89-6
• Molecular Formula: C₁₉H₂₈N₂O₆
• Molecular Weight: 380.44
• Mol File: 159634-89-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 592.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.175±0.06 g/cm3(Predicted)
• PKA: 3.11±0.10(Predicted)
• CAS DataBase Reference: N-2-(3-BENZYLOXY PRIOPIONIC ACID)-2-(N-T-BUTOXYCAR(CAS DataBase Reference)
• NIST Chemistry Reference: N-2-(3-BENZYLOXY PRIOPIONIC ACID)-2-(N-T-BUTOXYCAR(159634-89-6)
• EPA Substance Registry System: N-2-(3-BENZYLOXY PRIOPIONIC ACID)-2-(N-T-BUTOXYCAR(159634-89-6)

Safety Data

• Hazardous Substances Data: 159634-89-6(Hazardous Substances Data)

Upstream product

• 10433-52-0 O-benzyl-D-serine 
• 193273-93-7 (R)-3-Benzyloxy-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-propionic acid methyl ester 
• 30992-29-1 Boc-Aib-OH 
• 5445-44-3 O-benzylserine 
• 103290-07-9 2-tert-butoxycarbonylamino-2-methyl-propionic acid-2,5-dioxo-pyrrolidin-1-yl ester 

Downstream Products

• 159634-87-4 N-[(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-[(1,1-dimethyl-ethoxy)carbonyl]amino-2-methyl-propanamide 
• 191487-52-2 MK-677 
• 193273-66-4 capromorelin 
• 193274-09-8 {1-[2-(3a-(S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethylcarbamoyl]-1-methyl-ethyl}carbamic acid tert-butyl ester 
• 193274-08-7 {1-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethylcarbamoyl]-1-methyl-ethyl}carbamic acid tert-butyl ester 
• 1415234-53-5 2-amino-N-((2R)-3-(benzyloxy)-1-(2-(2-(dimethylamino)-2-oxoethyl)-1-oxo-4-phenyl-2,7-diaza spiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide 
• 1415235-07-2 tert-butyl 1-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-ylamino)-2-methyl-1-oxopropan-2-ylcarbamate 
• 1415235-81-2 tert-butyl 1-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-ylamino)-2-methyl-1-oxopropan-2-ylcarbamate 
• 1415234-80-8 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide 
• 1415235-83-4 tert-butyl 1-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-ylamino)-2-methyl-1-oxopropan-2-ylcarbamate 
• 1415234-86-4 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-3-phenyl-2,6-diazaspiro[3.5]nonan-6-yl)-1-oxopropan-2-yl)-2-methylpropanamide 
• 1415235-79-8 tert-butyl 1-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-ylamino)-2-methyl-1-oxopropan-2-yl carbamate 
• 1415235-68-5 tert-butyl 1-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-ylamino)-2-methyl-1-oxopropan-2-ylcarbamate 
• 1415234-55-7 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-isopropyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide 

Relevant articles and documents

Domino Aryne Annulation via a Nucleophilic-Ene Process

1,2-Benzdiyne equivalents possess the unique property that they can react with two arynophiles through iteratively generated 1,2- and 2,3-aryne intermediates. Upon rational modification on the second leaving group of these aryne precursors, a domino aryne annulation approach was developed through a nucleophilic-ene reaction sequence. Various benzo-fused N-heterocyclic frameworks were achievable under transition metal-free conditions with a broad substrate scope.

Combinations of β3 agonists and growth hormone secretagogues

This invention is directed to pharmaceutical compositions comprising β3adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.

Process for preparing growth hormone secretagogues

This invention relates to improved processes for preparing compounds of Formula II, and compounds of Formula III, wherein R1, R2, R3 and Prt are defined as set forth in the specification.